TIVCHIGH SIGNALFINANCIAL10-K

TIVC experienced severe financial deterioration with gross profit collapsing from $287K to just $2K while net losses expanded substantially to $8.9M.

The near-complete elimination of gross profit margin signals fundamental business model distress, as the company can barely cover direct costs of its products. Combined with substantially higher net losses and reduced revenue, this suggests TIVC is burning through cash at an unsustainable rate and may face going-concern issues if trends continue.

Comparing 2026-03-30 vs 2025-03-21View on EDGAR →
FINANCIAL ANALYSIS

TIVC's financial performance deteriorated sharply across all key metrics. Revenue declined by over one-third to $780K while gross profit virtually disappeared, falling from $287K to just $2K - indicating severe margin compression. Operating losses expanded to $7.9M as SG&A expenses grew meaningfully to $4.8M, while net losses increased substantially to $8.9M, reflecting a company struggling with fundamental profitability challenges.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
-99.3%
$287K$2K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Accounts Receivable
Balance Sheet
-60.3%
$174K$69K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Net Income
P&L
-57%
-$5.7M-$8.9M

Net income declined 57% — review whether driven by operations, interest costs, or non-recurring items.

SG&A Expense
P&L
+50.7%
$3.2M$4.8M

SG&A up 50.7% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Operating Income
P&L
-39.5%
-$5.7M-$7.9M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
-33.7%
$1.2M$780K

Revenue declined 33.7% — significant demand weakness or market share loss warrants investigation.

Operating Cash Flow
Cash Flow
-22.3%
-$5.7M-$7.0M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-21
ADDED
false --12-31 FY 2025 true true true false Our management team is primarily responsible for assessing and managing our strategic risk exposures, including material risks from cybersecurity threats, with assistance from third-party service providers.
Management oversees our cybersecurity process on a day-to-day basis, including those described in Risk Management and Strategy above.
Our audit and risk committee is tasked with general oversight of our risk management process, including risks from cybersecurity threats.
Members of management provide periodic briefings to the audit and risk committee of our board of directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
In furtherance thereof, the committee is responsible for monitoring and assessing strategic risk exposure.
+7 more — sign up free →
REMOVED
As of March 17, 2025, 620,137 shares of the registrant s common stock were outstanding.
and our non-invasive cervical vagus nerve stimulation research; the implementation of our business model and strategic plans for our business and technology; regulatory or legal developments in the United States and other countries; developments or disputes concerning patent applications, issued patents or other proprietary rights; our expectations regarding the effects of a potential recession, market volatility and macroeconomic factors on our business, our suppliers and our customers; and developments and projections relating to our competitors and our industry.
3 In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject.
4 PA RT I Item 1 Business As used in this Report, unless the context otherwise requires, references to we, us, our, Company, Tivic, and Tivic Health refer to Tivic Health Systems, Inc.
Business Overview Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →